1 recruiting, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Endocrine Therapy 1: new trials by email Literature Review of Endocrine Therapy 1 trials Research Report on Endocrine Therapy 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer Dalpiciclib, Trastuzumab (Herceptin), Pertuzumab - Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 57 | 2026-06-01 | 2026-05-28 |
| A Study of PF-06873600 in People With Cancer PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2 - HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer | Phase 1 / Phase 2 | Terminated | Pfizer | 155 | 2018-03-07 | 2025-11-14 |
Breast Neoplasms (2) · Breast Neoplasms, Male (1) · Carcinoma, Ovarian Epithelial (1) · Fallopian Tube Neoplasms (1) · Ovarian Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Pfizer (1) · Sun Yat-sen University (1)
Bulgaria (1) · Canada (1) · China (1) · Japan (1) · Russia (1) · Ukraine (1) · United States (1)